Author

L. Klareskog

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 3 Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

F. Wermeling· 2 shared A. Cavalli· 1 shared A. Espinosa· 1 shared A. Hensvold· 1 shared A. Piralla· 1 shared B. Raposo· 1 shared B. Rethi· 1 shared C. Gronwall· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

F. Wermeling

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Dnmt3a mutations limit normal and autoreactive Tfh differentiation

Y. Shen, Z. Li, S. V. Boddul, Z. Kasza, A. Espinosa, L. Klareskog, F. Wermeling

This study shows that Dnmt3a mutations impair Tfh differentiation, contributing to autoimmune joint inflammation and reduced immune responses.

bioRxiv · Feb 16, 2024 · PreprintImmunology

Conversion of monoclonal IgG to dimeric and secretory IgA restores neutralizing ability and prevents infection of Omicron lineages

H. Marcotte, Y. Cao, F. Zuo, L. Simonelli, J. C. Sammartino, M. Pedotti, R. Sun, I. Cassaniti, M. Hagbom, A. Piralla, J. Yang, L. Du, E. Percivalle, F. Bertoglio, M. Schubert, , Q. Pan-Hammarstrom

Engineered dimeric and secretory IgA1 neutralized Omicron variants with higher potency than parental IgG.

Proceedings of the National Academy of Sciences · Jan 9, 2024Peer-reviewedMicrobiology

Divergent and dominant anti-inflammatory effects of patient-derived anti-citrullinated protein antibodies (ACPA) in arthritis development

B. Raposo, M. G. Afonso, L. Israelsson, H. Wähämaa, R. Stalesen, F. Wermeling, A. Hensvold, C. Grönwall, B. Rethi, L. Klareskog, V. Malmström

This study shows that most patient-derived anti-citrullinated protein antibodies (ACPA) are anti-inflammatory, with some clones inhibiting arthritis while others promote disease, highlighting the complexity of ACPA's role in rheumatoid arthritis.

bioRxiv · Sep 30, 2022 · PreprintImmunology